Home/Pipeline/Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS

Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS

Acute Respiratory Distress Syndrome (ARDS)

Investigator-Initiated TrialActiveN/A

Key Facts

Indication

Acute Respiratory Distress Syndrome (ARDS)

Phase

Investigator-Initiated Trial

Status

Active

Company

Sedana Medical

About Sedana Medical

Sedana Medical's mission is to make inhaled sedation a standard therapy in intensive care, representing a significant shift from decades of IV sedation dominance. The company has achieved commercial traction in Europe with its integrated device-pharma platform, reporting 179 MSEK in 2024 sales, and is actively pursuing U.S. market entry through an Early Access Program. Its strategy focuses on direct sales in key European markets, expanding global distribution, and generating clinical evidence to drive adoption and achieve profitability in its ex-U.S. operations.

View full company profile

Therapeutic Areas

Critical Care Sedation

Other Acute Respiratory Distress Syndrome (ARDS) Drugs

Drug	Company	Phase	Status
MultiStem	Athersys	Phase 3	Active (subject to funding)
BXT-25	BioXyTran	Preclinical	Active
Bioengineered Surfactant Program	BioSuperior	Pre-clinical	Active
FX06	F4 Pharma	Phase 1/2	Active
AVM0703	AVM Biotechnology	Pre-clinical / Research	Active
ACE2v2-Fc	Cyrus Biotechnology	Preclinical	Active
GEn-1124	GEn1E Lifesciences	Phase 2	Active
AZM-152	Azome Therapeutics	Pre-clinical	Active
Zelpultide Alfa	Airway Therapeutics	Pre-clinical/Research	Active
ALT-100 mAb	Aqualung Therapeutics	Phase 2a	Active
RP-323	PhorMed	Phase 2	Active
Research Grant: Effects of sevoflurane on lung water in ARDS	Sedana Medical	Investigator-Initiated Trial	Active